Medarex technology will be used to generate fully human mAbs against a Mitsubishi target.

Medarex is partnering with Mitsubishi Pharma to generate and evaluate fully human mAbs against a Mitsubishi target for the treatment of autoimmune diseases.

The companies will use Medarex’ UltiMAb Human Antibody Development System® to generate antibodies. The companies will share research responsibilities for any antibodies found through the collaboration.

Previous articlePreparing for Pandemic Flu
Next articleACE BioSciences In-Licenses CBL’s Travelers Diarrhea Vaccine